Hong Yuan Holding Group

HGYN: 10-Q · periodic report

Hong Yuan Holding Group (HGYN, OTCQB) filed its 10-Q for the quarter ended June 30, 2026, reporting revenue of just $32,161 versus $112,812 in the prior-year quarter, with six-month revenue falling to $75,858 from $353,877. The company swung to a net loss of $94,404 for the quarter (compared with net income of $30,042 a year earlier) and a net loss of $187,750 for the first six months of 2026, which it attributes to declining revenue at its Chinese VIEs and a 102.8% jump in quarterly operating expenses. Management disclosed substantial doubt about the company's ability to continue as a going concern: cash was only $13,365, the working capital deficit was $174,082, the accumulated deficit reached $97,840,395, and operations depend on advances from CEO and majority shareholder Li Xudong, who is owed $352,258 with no written commitment for further funding. The CEO also concluded that disclosure controls and procedures were not effective due to a weakness in the design of internal control over financial reporting, adding a governance red flag on top of the severe liquidity and operating deterioration.

SEC 10-Q•1mo ago

HGYN: 10-K/A · periodic report

Hong Yuan Holding Group filed a Form 10-K/A on September 14, 2026 covering fiscal year 2025, roughly eight and a half months after its December 31, 2025 year-end and about four months after the May 7, 2026 audit report date — a timing pattern that itself signals reporting strain. Auditor Aloba, Awomolo & Partners issued a going-concern qualification: revenue nearly tripled to $837,753 from $245,572 and the company swung to net income of $157,944 from a $96,437 loss, but cash was only $16,747 against a $97,652,645 accumulated deficit and an $11,622 working capital deficit, with operating cash flow still negative. Governance risk is extreme: CEO Xudong Li owns 67% of the common stock plus all 5,000,000 Series A-1 preferred shares (91% voting power), funds operations through $338,131 in on-demand loans, and controls 95% of the Chinese VIE at the center of the business; the company has also cycled through three audit firms since May 2024. The stock trades on OTC Pink under HGYN at penny-stock levels (as low as $0.002 in Q2 2025), and the entity's history includes a 2014 Chapter 7 bankruptcy conversion and a 1-for-50 reverse split under its prior identity as Cereplast — classic shell-revival red flags.

SEC 10-K/A•1mo ago

HGYN: NT 10-Q · late filing

Hong Yuan Holding Group filed a Form 12b-25 (NT 10-Q) on August 14, 2026, notifying the SEC it could not timely file its quarterly report for the period ended June 30, 2026. The company cited time constraints in compiling, disseminating and reviewing the required information, and undertook to file no later than five days after the original due date. Notably, the company checked 'Yes' to the question of whether a significant change in results of operations from the corresponding prior-year period is anticipated, yet attached no narrative or quantitative explanation. Investors are left without visibility into the direction or magnitude of that change until the actual 10-Q is filed. Additional risk context: Li Xudong signs the notification as both CEO and CFO — a governance concentration — and the registrant is a China-based company (Chengdu, Sichuan) that previously operated as Cereplast, Inc. The filing warrants close monitoring when the delayed quarterly report is released.

SEC NT 10-Q•2mo ago

HGYN: 10-Q · periodic report

Hong Yuan Holding Group reported a significant deterioration in financial performance for the quarter ended March 31, 2026, with revenue plummeting to $43,697 from $184,492 in the prior-year period. This decline in sales, attributed to reduced revenue from its Chinese VIEs, resulted in a net loss of $94,471 compared to net income of $37,357 in the same period last year. The company's liquidity position remains precarious, with cash and cash equivalents dropping to $6,444 as of March 31, 2026, from $16,747 at the end of 2025. The balance sheet reflects a net working capital deficit of $100,288 and a substantial accumulated deficit of $97.7 million, raising concerns about the firm's ability to fund ongoing operations. Management explicitly stated that there is substantial doubt about the company's ability to continue as a going concern due to its inability to generate sufficient revenue to cover costs and its reliance on debt and equity financing. The CEO, Xudong Li, has advanced funds for working capital, but the company notes there is no written agreement guaranteeing future support.

SEC 10-Q•4mo ago

HGYN: NT 10-Q · late filing

Hong Yuan Holding Group (formerly Cereplast, Inc.) filed a Form 12b-25 notification on May 15, 2026, stating it cannot file its Form 10-Q for the quarter ended March 31, 2026, by the prescribed deadline. The company cited 'time constraints' in compiling, disseminating, and reviewing required information as the reason for the delay, committing to file the report no later than five days after the original due date. Notably, the registrant indicated that 'significant change[s] in results of operations' are anticipated in the delayed report, raising concerns that the filing delay may be concealing material negative performance or accounting issues.

SEC NT 10-Q•5mo ago